Exact Mass: 317.1027
Exact Mass Matches: 317.1027
Found 64 metabolites which its exact mass value is equals to given mass value 317.1027,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
N2-Monodes-methylnizatidine
N2-Monodes-methylnizatidine is a metabolite of nizatidine. Nizatidine is a histamine H2-receptor antagonist that inhibits stomach acid production, and commonly used in the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD). It was developed by Eli Lilly and is marketed under the brand names Tazac and Axid. (Wikipedia)
N-2-Mdmn
2-{2-[4-(3,5-Dimethyl-1H-pyrazol-1-yl)phenyl]hydrazono}-2-(methylsulfonyl)acetonitrile
Methyl 2-cyano-3-(2-morpholino-5-nitrophenyl)acrylate
N,1,2,5-Tetra-Ac-beta-D-Furnose-3-Amino-3-deoxyribose
Oxyphenisatin
CONFIDENCE standard compound; INTERNAL_ID 625; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3927; ORIGINAL_PRECURSOR_SCAN_NO 3925 A - Alimentary tract and metabolism > A06 - Drugs for constipation > A06A - Drugs for constipation > A06AB - Contact laxatives C78276 - Agent Affecting Digestive System or Metabolism > C29697 - Laxative D005765 - Gastrointestinal Agents > D002400 - Cathartics CONFIDENCE standard compound; INTERNAL_ID 625; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3937; ORIGINAL_PRECURSOR_SCAN_NO 3935 CONFIDENCE standard compound; INTERNAL_ID 625; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3903; ORIGINAL_PRECURSOR_SCAN_NO 3901 CONFIDENCE standard compound; INTERNAL_ID 625; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3930; ORIGINAL_PRECURSOR_SCAN_NO 3928 CONFIDENCE standard compound; INTERNAL_ID 625; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3916; ORIGINAL_PRECURSOR_SCAN_NO 3914 CONFIDENCE standard compound; INTERNAL_ID 625; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3917; ORIGINAL_PRECURSOR_SCAN_NO 3916 CONFIDENCE standard compound; INTERNAL_ID 625; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7947; ORIGINAL_PRECURSOR_SCAN_NO 7945 CONFIDENCE standard compound; INTERNAL_ID 625; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7982; ORIGINAL_PRECURSOR_SCAN_NO 7981 CONFIDENCE standard compound; INTERNAL_ID 625; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7987; ORIGINAL_PRECURSOR_SCAN_NO 7982 CONFIDENCE standard compound; INTERNAL_ID 625; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8022; ORIGINAL_PRECURSOR_SCAN_NO 8020 CONFIDENCE standard compound; INTERNAL_ID 625; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8036; ORIGINAL_PRECURSOR_SCAN_NO 8034 CONFIDENCE standard compound; INTERNAL_ID 625; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8042; ORIGINAL_PRECURSOR_SCAN_NO 8039
2-quinolin-2-yl-1-[4-(trifluoromethyl)phenyl]ethanol
2,3-dihydroxybutanedioic acid,3-[1-hydroxy-2-(methylamino)ethyl]phenol
Metaraminol bitartrate
D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013566 - Sympathomimetics C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D002317 - Cardiovascular Agents > D014662 - Vasoconstrictor Agents
Imipenem
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D013845 - Thienamycins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic
1-(4-(4-Nitro-3-(trifluoromethyl)phenyl)piperazin-1-yl)ethanone
2-quinolin-4-yl-1-[4-(trifluoromethyl)phenyl]ethanol
(R)-2-(((BENZYLOXY)CARBONYL)AMINO)-3-(2-FLUOROPHENYL)PROPANOIC ACID
(S)-2-(((BENZYLOXY)CARBONYL)AMINO)-3-(2-FLUOROPHENYL)PROPANOIC ACID
(S)-2-(((BENZYLOXY)CARBONYL)AMINO)-3-(3-FLUOROPHENYL)PROPANOIC ACID
Methyl 4-(4-(Bis(2-Chloroethyl)Amino)Phenyl)Butyrate
Phenylephrine tartrate
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist
RS 127445
RS-127445 hydrochloride is a selective, high affinity, orally bioavailable 5-HT2B receptor antagonist with a pKi of 9.5. RS-127445 hydrochloride shows 1000 fold selectivity for this receptor as compared to numerous other receptor and ion channel binding sites[1].
ETHYL 2-((4-(BENZYLOXY)-3-FLUOROPHENYL)AMINO)-2-OXOACETATE
tert-butyl 4-[4-(chloromethyl)-1,3-thiazol-2-yl]piperazine-1-carboxylate
(R)-2-(2,5-difluorophenyl)pyrrolidine (R)-2-hydroxysuccinate
4,4,5,5-Tetramethyl-2-(2-nitro-5-(trifluoromethyl)phenyl)-1,3,2-dioxaborolane
6-methoxy-N-(4-methoxyphenyl)quinazolin-4-amine,hydrochloride
N-(2,2,4-trimethyl-2,3-dihydro-1-benzofuran-7-yl)benzenesulfonamide
2-(2-Deoxy-beta-D-erythro-pentofuranosyl)-7-hydroxypyrimido(1,6-a)benzimidazol-1(2H)-one
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-[2-(methylamino)ethyl]-2-sulfanylidenepyrimidin-4-one
1-[4-[2-Nitro-4-(trifluoromethyl)phenyl]piperazin-1-yl]ethanone
2-(3-Formyl-2,5-dimethyl-1-pyrrolyl)-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylic acid methyl ester
2-[[1-(4-Chlorophenyl)-4-pyrazolo[3,4-d]pyrimidinyl]amino]-1-butanol
1-(4-chlorophenyl)-N-(1-methoxypropan-2-yl)-4-pyrazolo[3,4-d]pyrimidinamine
2-[[2-furanyl(oxo)methyl]hydrazo]-N-(2-methoxy-5-methylphenyl)-2-oxoacetamide
3-[(1R,2S)-2-amino-1-hydroxypropyl]phenol dihydrogen (2R,3R)-2,3-dihydroxybutanedioate
N-(furan-2-ylmethyl)-N-[(Z)-(2-hydroxy-3-methoxyphenyl)methylideneamino]oxamide
(8E)-8-[(2-fluoroanilino)hydrazinylidene]-1,3-dimethylpurine-2,6-dione
N-[2-[(2Z)-2-[(2-hydroxy-3-methoxyphenyl)methylidene]hydrazinyl]-2-oxoethyl]furan-2-carboxamide
Oxyphenisatine
A - Alimentary tract and metabolism > A06 - Drugs for constipation > A06A - Drugs for constipation > A06AB - Contact laxatives C78276 - Agent Affecting Digestive System or Metabolism > C29697 - Laxative D005765 - Gastrointestinal Agents > D002400 - Cathartics
LY456236
LY456236 is a selective, non-competitive and orally active mGlu1 receptor antagonist that inhibits phosphoinositide hydrolysis with an IC50 of 0.145 μM. LY456236 also inhibits EGFR with an IC50 of 0.91 μM[1][3].
9-hydroxy-7-methoxy-13-methyl-10-azapentacyclo[9.7.1.0²,¹⁰.0³,⁸.0¹⁵,¹⁹]nonadeca-1,3(8),4,6,11,13,15(19),16-octaen-18-one
8-(1h-indol-3-yl)-2-methoxy-6-methylnaphthalene-1,4-dione
(4ar,7s)-6,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-5-methoxy-4a,7-dihydro-1λ⁴-chromen-1-ylium
acalyphine
{"Ingredient_id": "HBIN014320","Ingredient_name": "acalyphine","Alias": "NA","Ingredient_formula": "C13H19NO8","Ingredient_Smile": "CN1C=C(C(=CC1=O)OC)OC2C(C(C(C(O2)CO)O)O)O","Ingredient_weight": "0","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "23592","TCMSP_id": "NA","TCM_ID_id": "7249","PubChem_id": "NA","DrugBank_id": "NA"}
